Home » Drug Information » FDA Approved Drugs » 1997
Medical Areas: Endocrinology | Musculoskeletal
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Skelid (tiludronate disodium)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Approval Status: Approved March 1997
Treatment Area: Paget’s disease
Skelid, an orally-administered medicine, has been approved for
the treatment of Paget’s disease of bone, a common, potentially
debilitating bone disease. Skelid, a new bisphosphonate, has been
shown to be a strong inhibitor of bone resorption. It is
administered once a day, either in the morning or at night, and is
effective in a three-month dosage regimen, rather than the
six-month regimen normally employed for other currently-marketed
Studies submitted to the FDA show that Skelid can control the
abnormal bone growth of Paget’s disease without interfering with
the normal process of bone formation, as indicated by the
mineralization rate, bone remodeling and bone turnover.
The most frequent adverse events in patients receiving Skelid
included nausea, diarrhea and dyspepsia. Adverse events usually
were mild and generally did not require discontinuation of therapy.
Bisphosphonates may cause upper gastrointestinal disorders.
Paget’s disease is a chronic bone disease characterized by an
excessive rate of bone remodeling, resulting in the formation of
disorganized, enlarged and weakened bone structure. Second in
prevalence only to osteoporosis as a bone disease, Paget’s affects
an estimated 3 to 4% of the U.S. population over 50 years of age,
and is equally common in men and in women.